by 
Cancer remains one of the leading causes of mortality worldwide. While chemotherapy and radiation continue to be mainstay treatment options, their non-specific nature often leads to severe side effects affecting patient quality of life. There has been a growing need for targeted, minimally invasive treatment options. Gene therapy involves modification of gene expression or function using nucleic acids like DNA, RNA, antisense oligonucleotides etc. delivered utilizing viral or non-viral vectors. In personalized gene therapy, the treatment is customized for an individual’s specific cancer based on its molecular profile. This allows targeting the root cause of cancer at a genetic level. Several gene therapy products are in clinical trials involving insertion, deletion or correction of genes to make cancer cells more vulnerable, stimulate immune response or reduce tumor growth. Some trials have demonstrated encouraging response rates with manageable side effects.
The global Personalized Gene Therapy Treatments for Cancer Market is estimated to be valued at US$ 5 Billion in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023-2033, as highlighted in a new report published by Coherent Market Insights.
Market key trends: One of the major trends in the personalized gene therapy treatments for cancer market is the growing adoption of CRISPR/Cas9 genome editing technique. CRISPR/Cas9 allows precise editing of genes by cutting DNA at a desired location. This enables knocking out cancer causing genes or repairing genetic mutations underlying various cancers. CRISPR-based therapies are being evaluated in clinical trials for hematological as well as solid tumors. Their targeted approach represents a promising alternative to traditional treatment methods. With ongoing advancements, CRISPR is likely to transform the field of personalized cancer gene therapy in the coming years.
Porter’s Analysis
Threat of new entrants: Moderate to high costs of gene therapy research and development poses hindrance for new players.
Bargaining power of buyers: Patients have limited options, dependence on available treatment options increases buyers’ bargaining power.
Bargaining power of suppliers: High research costs related to development provide suppliers a competitive edge over others.
Threat of new substitutes: Ongoing research may lead to newer substitutes posing threat to existing personalized gene therapy treatments.
Competitive rivalry: Intense competition expected among players to develop customized treatments for various cancer types and gene mutations.
Key Takeaways
The global personalized gene therapy treatments for cancer market is expected to witness high growth. Advancements in genetic sequencing and identification of specific gene mutations driving the need for targeted therapies. Introduction of newer technologies for genetic diagnosis and therapy delivery further augment the market’s growth.
Regional analysis: North America dominates the global market and is expected to continue its lead position over the forecast period. Higher adoption of advanced treatment options and presence of supportive regulatory framework Aid the regions growth. The Asia Pacific market is witnessed significant growth attributed to growing investments for developing localized treatment facilities and options.
Key players: Key players operating in the personalized gene therapy treatments for cancer market are Gilead Sciences, Inc., Novartis AG, Bluebird Bio, Inc., Spark Therapeutics, Inc., UniQure N.V., Shanghai Sunway Biotech Co., Ltd., and Precision Biosciences. These players are focusing on developing customized treatments for a wide range of cancer types through organic and inorganic growth strategies.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it
